Search Results
Mar 05, 2026, 11:00 ET Francis Medical Announces First Commercial Vanquish® Procedures in Arizona for Prostate Tissue Ablation
adoption."In VAPOR 2 at 6-months, 91% of eligible patients showed elimination of targeted MRI visible, biopsy confirmed intermediate-risk disease (≥GGG2) following a single Vanquish procedure. The procedure was also well-tolerated, with no device-related serious adverse events and low rates of urinary
More news about: Francis Medical, Inc.
Feb 03, 2026, 10:00 ET Francis Medical Announces First Commercial Procedure with the Vanquish® Water Vapor System for Prostate Tissue Ablation
community."Six-month biopsy data on the first 110 patients in the VAPOR 2 study demonstrated elimination of targeted MRI visible, biopsy confirmed, intermediate risk (≥GGG2) disease in 91% of patients following a single Vanquish procedure. There were no device-related serious adverse events and low rates of urinary incontinence
More news about: Francis Medical, Inc.
Dec 02, 2025, 09:30 ET Francis Medical Receives FDA 510(k) Clearance for Use of the Vanquish® Water Vapor System for Prostate Tissue Ablation in Patients with Intermediate Risk Prostate Cancer
localized prostate cancer.Six-month biopsy data on the first 110 patients demonstrated elimination of targeted MRI visible intermediate risk (≥GGG2) disease in 91% of patients following a single Vanquish procedure. There were no device-related serious adverse events and low rates of urinary incontinence
More news about: Francis Medical, Inc.
Sep 23, 2025, 11:36 ET From Investment to Green Card: Golden Gate Global Celebrates another I-829 Approval as an EB-5 Industry Leader
Golden Gate Global (GGG), recognized as one of the top EB-5 regional centers, is proud to announce the first approval of an I-829 petition for an investor in its
More news about: Golden Gate Global
Sep 23, 2025, 11:36 ET From Investment to Green Card: Golden Gate Global Celebrates another I-829 Approval as an EB-5 Industry Leader
Golden Gate Global (GGG), recognized as one of the top EB-5 regional centers, is proud to announce the first approval of an I-829 petition for an investor in its
More news about: Golden Gate Global
Jun 21, 2025, 21:35 ET Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions
that multiple exploratory mechanism-of-action (MoA) analyses of mazdutide (investigator-initiated trials) as well as a preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased at the American Diabetes Association's (ADA) 85th Scientific Sessions. Details are listed below：
More news about: Innovent Biologics
Jun 12, 2025, 21:00 ET Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
mazdutide in Chinese adults with T2D (DREAMS-1). In addition, multiple exploratory MoA analyses of mazdutide as well as preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased in poster presentations. Details are listed below： Title: Mazdutide vs. Placebo as Monotherapy
More news about: Innovent Biologics